EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Iron chelation improves endothelial function in patients with coronary artery disease



Iron chelation improves endothelial function in patients with coronary artery disease



Circulation 103(23): 2799-2804



Background: Some epidemiological studies have shown that increased iron stores are associated with increased cardiovascular events. Redox-active iron may contribute to lipid peroxidation, endothelial cell activation, and generation of reactive oxygen species (especially hydroxyl radical, via Fenton chemistry). Increased oxidative stress is associated with impaired action of endothelium-derived nitric oxide in patients with atherosclerosis. Methods and Results: To test the hypothesis that reducing vascular iron stores would reverse endothelial dysfunction, we examined the effects of the iron chelator deferoxamine (500 mg intra-arterially over 1 hour) on vasomotor function in forearm resistance vessels of patients with coronary artery disease by venous occlusion plethysmography. Patients with coronary artery disease had impaired endothelium-dependent vasodilation in response to methacholine compared with healthy control subjects (P<0.001). Deferoxamine infusion decreased serum iron levels (P<0.001). Deferoxamine improved the blood flow response to methacholine in patients with coronary artery disease (P<0.01 by 2-way repeated-measures ANOVA) but had no effect on the response to sodium nitroprusside. In normal volunteers, deferoxamine had no effect on the response to methacholine. The nitric oxide synthase inhibitor NG-monomethyl-L-arginine abolished augmentation of the methacholine response associated with deferoxamine. The hydroxyl radical scavenger mannitol had no effect on the methacholine response. Conclusions: Deferoxamine improved nitric oxide-mediated, endothelium-dependent vasodilation in patients with coronary artery disease. These results suggest that iron availability contributes to impaired nitric oxide action in atherosclerosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 010885083

Download citation: RISBibTeXText

PMID: 11401935

DOI: 10.1161/01.CIR.103.23.2799



Related references

Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. Journal of the American College of Cardiology 41(3): 420-425, February 5, 2003

Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. Journal of International Medical Research 38(1): 86-94, 2010

Iron chelation with deferoxamine improves endothelial function in patients with atherosclerosis. Circulation 100(18 SUPPL ): I 756, Nov 2, 1999

Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radical Biology & Medicine 39(9): 1184-1190, 2005

Darbepoetin improves endothelial function and increases circulating endothelial progenitor cell number in patients with coronary artery disease. Heart 97(18): 1474-1478, 2011

Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. Journal of Cardiovascular Pharmacology 35(2): 173-178, 2000

Treatment with folic acid and cobalamin improves coronary endothelial function in hyperhomocysteinemic patients with symptomatic coronary artery disease. Journal of the American College of Cardiology 37(2 Supplement A): 319A, February, 2001

Treatment with folic acid and cobalamin improves coronary endothelial function in hyperhomocysteinaemic patients with symptomatic coronary artery disease. European Heart Journal 22(Abstract Supplement): 129, September, 2001

Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation 107(25): 3152-3158, 2003

Ranolazine improves endothelial function in patients with stable coronary artery disease. Coronary Artery Disease 20(5): 343-347, 2009

Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 108(3): 164-169, 2006

Nifedipine improves coronary and peripheral endothelial function in patients with coronary artery disease: are calcium channel blockers acquitted on the charges?. International Journal of Cardiology 116(3): 406-407, 2006

Exercise training improves coronary endothelial function and flow reserve in patients with coronary artery disease Does a dose-response relationship exist?. European Heart Journal 21(Abstract Supplement): 494, August-September, 2000

Enhanced external counterpulsation improves endothelial function in patients with coronary artery disease. Journal of the American College of Cardiology 41(6 Supplement A): 370A, March 19, 2003